Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Based on the outstanding expertise and rich experience, Creative Biolabs has specially developed a system approach of TCR generation and optimization for TCR development. The phage surface display is an effective technology optimized by our expert team, which will be signally promote the ability of recognition to tumor antigen.
T cells expressing antigen-specific TCRs mediate the elimination of tumor and virally infected cells by recognition of antigen in the form of individual peptides bound to MHC molecules. Although interactions between TCR and the restriction MHC element have been detected only in the presence of specific peptides, it is believed that this thymic-positive selection imposes a low self-MHC affinity onto the peripheral T cell pool. Several creative approaches have been used to generate TCRs that are specific for other antigens expressed by a wider variety of tumor cell types.
In order not to generate T cell clones depending on the ability, yet allowing for the selection of high-affinity TCRs that are reactive against a variety of antigens, Creative Biolabs has developed a remarkable method that does not require patient material to obtain a tumor-antigen-reactive. TCR is use of phage display technology for TCR isolation. This approach, which bypasses the need for a T-cell clone, may be generically suitable for isolation of antigen-specific TCRs from polyclonal T-cell populations.
Creative Biolabs has the capability to enable you to free up your time for core work and project. Our service can be designed to meet your special needs if you have any requirements. If you are interested in our service, please contact us by E-mail and our team will get back to you as soon as possible.
Reference
Tristen S. Park, et al. Treating cancer with genetically engineered T cells. Trends in Biotechnology, 2011, 29 (11): 550-557.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
